Janus Global Life Sciences Fund (JAGLX)

Sector Experts Seeking Growth and Innovation in Health Care

SHARE CLASS

FUND FACTS (JAGLX)

Inception Date12/31/1998
NAV (As of 7/28/15 )$65.50
Total Net Assets (As of 6/30/15)$4.99B
Annual Expense Ratio
(As of fiscal year end 9/30/14)
GROSS 0.93%
NET 0.93%

Performance (As of 6/30/15)
1 Year40.08%
3 Year39.10%
5 Year31.38%
10 Year15.39%
Morningstar (As of 6/30/15)
CategoryHealth
Overall Rating™
(Based on risk-adjusted returns)

View All Ratings

123 Funds Rated
Equity
Style Box

Returns quoted are past performance and do not guarantee future results; current performance may be lower or higher. Investment returns and principal value will vary; there may be a gain or loss when shares are sold. For the most recent month-end performance click here.

Client Commitment

This global health care fund seeks consistent returns by investing in companies addressing unmet medical needs or making the health care system more efficient. We balance the portfolio across pharmaceuticals, biotechnology and services/devices sub-sectors in an effort to achieve similar or lower volatility relative to our peers. 

Client Commitment Video

Why Invest in the Fund

FINDING GROWTH IN HEALTH CARE

In addition to the powerful demographic trends affecting the sector, health care is also experiencing acceleration in innovation. The Fund seeks to invest in growth companies that are addressing unmet medical needs or making the health care system more efficient and affordable.

DEDICATED SECTOR EXPERTS

Our dedicated team of analysts has more than 75 years of combined experience investing in health care companies. In this complex and rapidly growing sector, we believe it is critical to have an experienced team that seeks to understand both the science and the business of the companies in which they invest.

DEEP AND DISCIPLINED

We believe the combination of deep fundamental research and disciplined portfolio construction will lead to consistently strong results relative to both the health care sector and the broader equity market. The Fund is balanced across the subsectors of health care and diversified across market-cap segments and geographies.

Results

Competitive Risk-Adjusted Performance Across the Board
Risk-Adjusted Performance (Alpha) compared to Peer Average as of 6/30/15
Based on the Fund’s “parent” share class (typically that with the longest history).Performance varies by share class.
Alpha compares the risk-adjusted performance of the Fund and Peer Group to the MSCI World Health Care Index. A positive alpha means the portfolio has outperformed the index on a risk-adjusted basis.Statistics are for the Fund's "parent" share class (typically that with the longest history).

FUND MANAGEMENT

Andy Acker, CFA

Andy Acker, CFA

Fund Manager since 2007
Industry since 1996

FUND NEWS

Fortune Biotech pro's top 8 stock picks Global Life Sciences 

Barron's Undervalued Biotech Stocks Help Fund Beat the Index Global Life Sciences

MORNINGSTAR TOOLS

Go beyond ratings with our Fund vs. Fund, Portfolio Analysis and Portfolio Comparison tools powered by Morningstar.